Odylia and Foundation Fighting Blindness are hosting a 4-part preclinical and translational research webinar series. The series will focus on genetic technologies and will provide advice and educational materials to researchers in the rare disease space. If you are currently working in or thinking about preclinical...
Converting vertical information approaches into horizontal solutions for all members of the rare disease community....
Meet members of the Odylia team at the JP Morgan Healthcare Conference. We would love to connect....
Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships....
Dr. Robinson brings extensive biotech experience in gene therapy, ophthalmology and more...
Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for multiple rare and ultra-rare diseases. He brings to Odylia vast knowledge...
SOUTH PLAINFIELD, N.J., and BOSTON, M.A. - July 1, 2019 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system developed by researchers at Massachusetts...
Lara Aronoff Dorfman joins Odylia Therapeutics as the Director of Business Development. Her focus for this unique nonprofit biotech company will be raising capital through philanthropy, primarily from foundations and corporate giving. Increased funds will allow Odylia to have a greater impact on shifting the...
Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast. A recording of the podcast entitled “Rare Disease, Cell and Gene Therapy Weekly Roundup” can be found here. Produced by Partners4Access, global experts in access for orphan drug, cell and gene...
Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues restricting the development and clinical application of gene therapies for rare genetic diseases. He discussed the specific challenges facing ultra-rare indications, especially those...